Vice President, Compliance and Chief Compliance Officer
Kate Farrington, current chief compliance officer (CCO) of Melinta, has more than 25 years of experience specializing in healthcare compliance and information technology in the pharmaceutical industry. Prior to joining Melinta, Ms. Farrington served as president and owner of Farrington Consulting, LLC where she provided compliance consulting services. Before starting Farrington Consulting, LLC, Ms. Farrington was the director of compliance at Luitpold Pharmaceuticals, Inc. where she was responsible for the implementation of Corporate Integrity Agreement (CIA) requirements received by sister company Daiichi Sankyo, Inc. in the applicable divisions of Luitpold Pharmaceuticals, Inc. Prior to joining Luitpold Pharmecuticals, Inc. she led both the sample compliance department and the aggregate spend & reporting function for Forest Laboratories which included Compliance program execution, oversight of department operations and the design, implementation and 21 CFR Part 11 validation of several Sales & Compliance technology solutions including custom designed in-house systems as well as off the shelf packages. Upon the Actavis, plc acquisition of Forest, she consolidated all Actavis companies into one spend solution. Ms. Farrington earned a B.A. in Business Administration from Marymount Manhattan College and her certificate of healthcare compliance from Seton Hall Law School.